Skip to content
OpenCapital
Get started

Nuvation Bio NUVB Fair Value Adjustment Of Warrants

Fair Value Adjustment Of Warrants at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$295.41M+65,840%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's fair value adjustment of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's fair value adjustment of warrants?
Nuvation Bio (NUVB) reported fair value adjustment of warrants of -$2.87M in Q1 2026.
How has Nuvation Bio's fair value adjustment of warrants changed year-over-year?
Nuvation Bio's fair value adjustment of warrants decreased by 481.5% year-over-year, from $751K to -$2.87M.
What is the long-term trend for Nuvation Bio's fair value adjustment of warrants?
Over 4 years (2021 to 2025), Nuvation Bio's fair value adjustment of warrants has grown at a -33.8% compound annual growth rate (CAGR), from -$4.23M to $812K.
What does fair value adjustment of warrants mean?
Captures the periodic change in the fair market value of outstanding warrants classified as liabilities. Fluctuations in this metric are driven by changes in the company's stock price and volatility, impacting net income without affecting cash flow.